Category: InVivo Therapeutics Corp.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic tendonitis.
Pluristem (NSDQ:PSTI) announced a new Phase I clinical trial to treat chronic tendonitis with the company's PLX-PAD stem cell therapy.
Cell therapy has traditionally been used in cancer and cardiac treatments, but Pluristem is now applying the technology to sports-related injuries, where it has seen an increased interest among athletes and orthopedic surgeons.
InVivo Therapeutics shares rose today on Wall Street as investors reacted to its pursuit of a listing on a major stock exchange, despite wider operating losses for the pre-revenue company.
Shares of InVivo Therapeutics (OTC:NVIV) area up today despite wider 1st-quarter operating losses, as investors react to news that the medical device company will seek a listing on either the New York Stock Exchange or the NASDAQ exchange.
Spinal devices maker InVivo Therapeutics expects to raise $10.4 million from a call for early exercise of warrants issued in 2010.
Massachusetts-based spinal devices maker InVivo Therapeutics (OTC:NVIV) announced an early call for exercise of warrants issued in 2010, expecting to raise $10.4 million.
Under the terms of the warrants, InVivo has the right to call for early exercise because NVIV shares have traded above $2.80 per share for 20 consecutive days, which occurred yesterday.
Topera offers details on its $25 million Series C round, first reported last month on MassDevice.com.
Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.
The FDA approved Invivo Therapeutics' biopolymer scaffold product under Investigational Device Exemption, clearing the way for human trials
InVivo Therapeutics (OTC:NVIV) said the FDA has given the company the green light to begin the first human clinical studies of its bioploymer scaffold, which treats traumatic spinal cord injury.
The Cambridge, Mass.-based company said it is gearing up for safety studies in 5 patients over 15 months, and is shooting for Institutional Review Board (IRB) approval at Massachusetts General Hospital.
InVivo Therapeutics wins humanitarian use device status from the FDA for its biopolymer scaffold, designed to treat spinal cord injuries, clearing the way for approval of a pivotal trial.
InVivo Therapeutics (OTC:NVIV) said the FDA deemed its biopolymer scaffold, designed to treat spinal cord injuries, to be a humanitarian use device.
The designation means the InVivo scaffold can seek expedited approval from the FDA for a pivotal trial of the device. HUD-based exemptions cover devices aimed at treating rare diseases and health problems, so-called "orphan" conditions.
InVivo Therapeutics says it's updated its application for an investigation device exemption from the FDA to begin human testing on its acute spinal cord injury treatment.
InVivo Therapeutics (OTC:NVIV) hopes to begin testing in humans in an open-label safety and efficacy study now that it's updated its submission for an investigational device exemption submission for its spinal cord injury treatment.
InVivo filed the original investigational device exemption application in July 2011, but has yet to be approved.